Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.

Saved in:
Bibliographic Details
Title: Clinical outcomes and predictors of response to PD-(L)1 blockade in patients with NSCLC without actionable genomic alterations who never used tobacco.
Authors: Gariazzo E; Dana-Farber Cancer Institute Boston, Massachusetts United States., Elkrief A; Memorial Sloan Kettering Cancer Center New York United States., Concannon K; The University of Texas MD Anderson Cancer Center United States., Ognissanti D; University of Perugia Perugia Italy., Dodi A; Ospedale di Parma Parma Italy., Favorito V; Institut Gustave Roussy Villejuif France., Di Federico A; Memorial Sloan Kettering Cancer Center New York United States., De Giglio A; Policlinico S.Orsola-Malpighi Bologna Italy., Brunetti L; Imperial College London London United Kingdom., Santo V; Dana-Farber Cancer Institute Boston United States., Pecci F; Dana-Farber Cancer Institute Boston, Massachusetts United States., Aldea M; Institut Gustave Roussy Villejuif, Massachusetts France., Garbo E; Dana-Farber Cancer Institute Boston, Massachusetts United States., Alessi JV; Dana-Farber Cancer Institute Boston, MA United States., LoPiccolo J; Dana-Farber Cancer Institute Boston United States., Paoloni F; Dana-Farber Cancer Institute Boston, MA United States., Nishino M; Dana-Farber/Brigham and Women's Cancer Center Boston, MA United States., Sholl LM; Brigham and Women's Hospital Boston, MA United States., Florez N; Dana-Farber Cancer Institute United States., Rotow J; Dana-Farber Cancer Institute Boston, MA United States., Frumm SM; Dana-Farber Cancer Institute Boston, MA United States., Hong L; The University of Texas MD Anderson Cancer Center Houston, TX United States., Zhang J; The University of Texas MD Anderson Cancer Center Houston, TX United States., Gibbons D; The University of Texas MD Anderson Cancer Center Houston, TX United States., Wang X; Harvard University Boston, MA United States., Landi L; Istituti Fisioterapici Ospitalieri Italy., Cipriani L; Instituto Nazionale Tumori Regina Elena Rome, RM Italy., Rakaee M; Brigham and Women's Hospital Boston United States., Cortellini A; Università Campus Bio-Medico Rome Italy., Tiseo M; Ospedale di Parma Parma Italy., Cappuzzo F; Instituto Nazionale Tumori Regina Elena Rome Italy., Ardizzoni A; University of Bologna Bologna Italy., Awad MM; Dana-Farber Cancer Institute Boston, Massachusetts United States., Heymach JV; The University of Texas MD Anderson Cancer Center Houston, TX United States., Scalera S; Instituto Nazionale Tumori Regina Elena Rome Italy., Maugeri-Saccà M; Instituto Nazionale Tumori Regina Elena Rome Italy., Metro G; University of Perugia Perugia Italy., Vokes N; The University of Texas MD Anderson Cancer Center Houston, TX United States., Schoenfeld A; Memorial Sloan Kettering Cancer Center New York, NY United States., Ricciuti B; Dana-Farber/Harvard Cancer Center Boston, Massachusetts United States.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2026 May 18. Date of Electronic Publication: 2026 May 18.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-25-4793